Skip to main content

Table 1 The relationship between the expression of CBR3-AS1 and the clinicopathological characteristics of BRCA patients

From: LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway

Factors

Number (96)

CBR3-AS1 expression

χ2

ap-value

Low (42)

High (54)

Age (years)

 < 50

44

20

24

0.0959

0.7568

 ≥ 50

52

22

30

Tumor size (cm)

 < 3

46

26

20

5.854

0.0155*

 ≥ 3

50

16

34

ER

 positive

49

20

29

0.35

0.5541

 negative

47

22

25

PR

 positive

50

19

31

0.9567

0.328

 negative

46

23

23

Her2

 positive

51

22

29

1.92E-05

0.9965

 negative

44

19

25

Molecular typing

 Luminal A

33

15

18

0.5994

0.8966

 Luminal B

32

13

19

 Her-2

18

9

9

 Basal-like

13

5

8

staging

 I

22

15

7

7.127

0.0283*

 II

44

17

27

 III

30

10

20

  1. * p < 0.05
  2. aChi-square test